Iris Isufi, MD

Assistant Professor of Medicine (Hematology)

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Hematology

Cancer Center: Hematology Program

Transplantation Center

Yale Medicine

Office of Cooperative Research

Board Certifications

  • Internal Medicine AB of Internal Medicine (2007)

  • Medical Oncology AB of Internal Medicine (2011)

Clinical Trials

Conditions Study Title
Hodgkin's Lymphoma A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
Lymphoid Leukemia, Phase I An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma A Phase III Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma
Non-Hodgkin's Lymphoma A Phase I/II Study of Intratumoral G100 Therapy in Patients With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin's Lymphoma
Mycosis Fungoides, Phase I A Phase I Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral and Subcutaneous Injection in Patients With Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-type
Hodgkin's Lymphoma, Leukemia, other, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Hematopoietic, Phase I An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Non-Hodgkin's Lymphoma, Other Hematopoietic Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma
Multiple Myeloma A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Patients With Multiple Myeloma (MM)

Edit this profile

Contact Info

Iris Isufi, MD
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste North Pavilion 7

New Haven, CT 06510
View on map...
Mailing Address
333 Cedar Street FMP 130
PO Box 208032

New Haven, CT 06520-8032